RISKYCAD

Personalized diagnostics and treatment of high risk coronary artery disease patients

Coordinatore	"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"    more  Organization address address: Soranou Efesiou 4 city: ATHENS postcode: 11527 contact info Titolo: Mr. Nome: Dimitris Cognome: Raptis Email: send email Telefono: 302107000000 Fax: 302107000000
Nazionalità Coordinatore	Greece [EL]
Totale costo	7˙901˙915 €
EC contributo	5˙992˙101 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-11-01   -   2017-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"  Organization address address: Soranou Efesiou 4 city: ATHENS postcode: 11527 contact info Titolo: Mr. Nome: Dimitris Cognome: Raptis Email: send email Telefono: 302107000000 Fax: 302107000000	EL (ATHENS)	coordinator	1˙135˙720.00
2	COMPREHENSIVE BIOMARKER CENTER GMBH  Organization address address: IM NEUENHEIMER FELD 519 city: HEIDELBERG postcode: 69120 contact info Titolo: Dr. Nome: Markus Cognome: Beier Email: send email Telefono: +49 6221 6510 380 Fax: +49 6221 6510 329	DE (HEIDELBERG)	participant	671˙000.00
3	ZORA BIOSCIENCES LTD  Organization address address: Biologinkuja 1 city: ESPOO postcode: 2150 contact info Titolo: Ms. Nome: Riikka Cognome: Katainen Email: send email Telefono: 358406000000	FI (ESPOO)	participant	641˙898.00
4	RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG  Organization address address: SEMINARSTRASSE 2 city: HEIDELBERG postcode: 69117 contact info Titolo: Dr. Nome: Ralf Cognome: Weigel Email: send email Telefono: 496214000000 Fax: 496214000000	DE (HEIDELBERG)	participant	640˙400.00
5	UNIVERSITAET ZUERICH  Organization address address: Raemistrasse 71 city: ZURICH postcode: 8006 contact info Titolo: Prof. Nome: Ulf Cognome: Landmesser Email: send email Telefono: +41 44 255 95 95	CH (ZURICH)	participant	581˙000.00
6	TAMPEREEN YLIOPISTO  Organization address address: Kalevantie 4 city: TAMPERE postcode: 33014 contact info Titolo: Ms. Nome: Susanna Cognome: Airila Email: send email Telefono: +358 50 318 6381	FI (TAMPERE)	participant	545˙000.00
7	A. PERSIDIS & SIA OE  Organization address address: RODOPOLEOS STREET 34 city: Athens postcode: 16777 contact info Titolo: Dr. Nome: Andreas Cognome: Persidis Email: send email Telefono: 302110000000	EL (Athens)	participant	497˙000.00
8	UNIVERSITA DEGLI STUDI DI MILANO  Organization address address: Via Festa Del Perdono 7 city: MILANO postcode: 20122 contact info Titolo: Mr. Nome: Sergio Cognome: Longo Email: send email Telefono: 390250000000 Fax: 390250000000	IT (MILANO)	participant	444˙000.00
9	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Ms. Nome: Linda Cognome: Pialek Email: send email Telefono: +44 1865 289800 Fax: +44 1865 289801	UK (OXFORD)	participant	399˙463.00
10	GENOWAY S.A.  Organization address address: Avenue Jean Jaures 181 city: LYON postcode: 69362 contact info Titolo: Mrs. Nome: Gaelle Cognome: Le Bel Email: send email Telefono: +33 4 37 65 41 00 Fax: +33 4 37654101	FR (LYON)	participant	364˙620.00
11	SYNLAB HOLDING GMBH  Organization address address: GUBENER STRASSE 39 city: AUGSBURG postcode: 86156 contact info Titolo: Prof. Nome: Winfried Cognome: März Email: send email Telefono: +49 621 43179432 Fax: +49 621 43179433	DE (AUGSBURG)	participant	72˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Although the accurate diagnosis and prevention of coronary artery disease (CAD), acute myocardial infarction (AMI) and death is a major public health issue, risk stratification for CAD with current diagnostic tools is not properly supporting clinical decision making. RiskyCAD’s overall goal is to identify novel biomarkers for asymptomatic patients in high risk of major coronary events, and develop new diagnostic tools and ‘personalized’ therapeutic strategies for this selected group of patients.

Taking advantage of the latest technologies, we will look into new biomarkers for asymptomatic patients in high risk of CAD using some of the finest cohorts (WP1), identify new molecules and develop new diagnostic kits that will be further validated in additional cohorts (WP6). We will generate reprogrammed iPS cell based human models for the study of metabolic aberrations in selected individual vulnerable CAD patients (WP2). We will identify defects, e.g. in liver lipid metabolism, in high risk CAD patients (WP3) and test targeted treatments in traditional and new preclinical animal models to provide proof-of-concept level evidence (WP4, WP5). As our approach is based on well characterized patients and phenotypes, we will generate clinically applicable stratification methods that will allow targeted treatment and patient enrichment for clinical trials (WP1). Unique predictive modelling and link identification platforms including Drug Repositioning will be used to select drugs or drug combinations that will best match the patient’s biomarker profile (WP7).

The final (translational) outcomes of this project will be: (i) a set of distinct biomarker test(s) for asymptomatic patients in high risk of CAD that can be ordered both by primary care physicians and specialized cardiologists from routine clinical laboratories; (ii) new CAD risk estimation models; (iii) a set of repositioned drugs ready to be exploited further for the optimal treatment of patients in high risk of CA'

Introduzione (Teaser)

In the developed world, cardiovascular events such as coronary artery disease (CAD) and myocardial infarction (MI) are major causes of death. There is a need for accurate risk stratification and new diagnostic tools to personalise therapy.